Research Library
Latest Published Research
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
This prospective, longitudinal study comprised six sequential surveys that collected data from adults planning to take psilocybin outside clinical research: at time of consent, 2 weeks before, the day before, 1–3 days after, 2–4 weeks after, and 2–3 months after. Results from this study, the largest prospective survey of naturalistic psilocybin use to date, support the potential for psilocybin to produce lasting improvements in mental health symptoms and general wellbeing.
Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study
We observed increases in mind perception across a variety of living and non-living targets (e.g., plants, animals). However, we found little to no change in metaphysical beliefs (e.g., dualism) or Atheist-Believer status. Taken together, these findings contrast with those from cross-sectional studies that psychedelic experiences result in changes to Atheist-Believer status and non-naturalistic beliefs but support the relevance of mind perception and mentalization.
Download the PDF and read about our results.
Published in PsyArXiv
Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
Acute experiences of shame or guilt occur commonly with psilocybin, are generally mild in nature but also range to more severe, and are predicted by younger age (for both shame and guilt) and higher trait anxiety (for shame only). In this sample, approximately two-thirds reported some degree of guilt or shame during psilocybin use. Psilocybin on average produces small but enduring decreases in trait shame within the context of largely purposeful and intentional use.
Download the PDF and read about our results.
Published in PsyArXiv
Use the Search Fields to Find Information
Page 4 of 27
When the Trial Ends: The Case for Post‑Trial Provisions in Clinical Psychedelic Research
Abstract The ethical value—and to some scholars, necessity—of providing trial patients with post-trial access (PTA) to an investigational drug has been subject to significant attention in the field of research ethics. Although no consensus has emerged, it seems clear that, in some trial contexts, various factors make PTA particularly appropriate. We outline the atypical aspects […]
March 18, 2024
Self-perception and self-recognition while looking in the mirror on psilocybin
ABSTRACT Introduction: It is not known how self-perception and self-recognition are influenced when one is highly self-focused under the influence of psilocybin. Here we examine self-reports of mirror self-recognition and self-perception during a psilocybin experience. Methods: Reddit posts were examined in a systematic manner. Posts that were written by individuals that ingested psilocybin […]
Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics
Abstract Background: Individuals who use psychedelics take efforts to mitigate unintended consequences. Despite the demonstrated utility of analogous protective behavioral strategies (PBS) assessments for other substances, no standardized scale exists to capture these protective strategies for psychedelic use. Objective: The present study addresses a notable gap concerning the assessment of psychedelic use, specifically […]
March 17, 2024
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Abstract We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. In a randomized, waiting list-controlled clinical trial for major depressive disorder in adults (N = 24), participants were randomized […]
March 14, 2024
Adolescent Psychedelic Use and Psychotic or Manic Symptoms
IMPORTANCE While psychedelic-assisted therapy has shown promise in the treatment of certain psychiatric disorders, little is known about the potential risk of psychotic or manic symptoms following naturalistic psychedelic use, especially among adolescents. OBJECTIVE To investigate associations between naturalistic psychedelic use and self-reported psychotic or manic symptoms in adolescents using a genetically informative design. […]
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Abstract Although there is a growing support for the protective factor of psychedelics to improve mental and physical health, these effects may differ across racial and ethnic groups. Race differences remain a critically understudied gap in psychedelic literature. Recent empirical research into Minority Diminished Psychedelic Returns suggests that Black Americans may gain little health […]
Minorities’ diminished psychedelic returns
Abstract Although there is a growing support for the use of psychedelics to improve the health of marginalized groups, there are some critical gaps. First, no empirical studies have examined the effects of psychedelics on Black Americans. Second, there is little research on population effects of psychedelics. Third, little research has tested how cultural […]
Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users
ABSTRACT Growing research exploring the utility of psychedelic substances suggests that they not only hold promise for clinical practice but may enhance mental health through recreational use as well. However, given the importance of set and setting for maximizing benefits and minimizing harms of drug use, it is important to develop a foundational understanding […]
March 12, 2024
Diminished psychedelic returns on distress: Marital status and household size
Abstract Although the use of psychedelics to impact health has seen growth, little research has tested the effects of culture conditions on the relationship. More specifically, how does marital status and family size affect the relationship between psychedelics and health? This study tests the relationship between Lifetime Classic Psychedelic Use (LCPU), marital status, and […]
Psychedelic Medicine’s Future Depends on Proactive Development of a Robust Medical Billing and Coding Strategy
Abstract Background: Although still investigational, psychedelic therapies appear poised to begin securing regulatory approval as medical treatments in the United States within the next 2 years. If approved, one of the most daunting barriers to equitable patient access to these novel treatments is their incorporation into the medical billing and coding system. Since specific […]
March 11, 2024
Page 4 of 27